Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03620058 | CART22 Alone or in Combination With huCART19 for ALL | active not recruiting | Phase 1 | 23 | University of PennsylvaniaOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT07014462 | A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML(DLIT-AML) | enrolling by invitation | Phase 1 | 20 | University of VermontOTHER | 1 |
| Oct 6, 2025 |
| clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT06307054 | CLL-1 CAR-NK Cells for Relapsed/Refractory AML | recruiting | Phase 1 | 24 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198867 | A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04606433 | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 47 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05705570 | Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies(CARTHIAE-1) | recruiting | Phase 1 | 30 | Nelson HamerschlakOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06501196 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 170 | BlossomHill TherapeuticsINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05993949 | Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 8 | Stanford UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05192889 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | active not recruiting | Phase 1 / Phase 2 | 35 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06037018 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | recruiting | Phase 1 | 44 | CytoCares IncINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06709469 | Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults(REALL_CART) | recruiting | Phase 1 | 10 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06281847 | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia(RESOLVE AML001) | not yet recruiting | Phase 1 / Phase 2 | 143 | Advesya SASINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART E) | not yet recruiting | Phase 1 / Phase 2 | 42 | Princess Maxima Center for Pediatric OncologyOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT04150497 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | recruiting | Phase 1 / Phase 2 | 52 | Cellectis S.A.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT07162116 | A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants(XY0206-CQT) | recruiting | Phase 1 | 45 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07109518 | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT07131085 | QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 20, 2025 | clinicaltrials |
| NCT06378437 | A Study of GLB-001 in Patients With Myeloid Malignancies | recruiting | Phase 1 | 108 | Hangzhou GluBio Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05667506 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | recruiting | Phase 1 / Phase 2 | 47 | Juventas Cell Therapy Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | recruiting | Phase 1 | 36 | University Hospital TuebingenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106749 | CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07066397 | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL | recruiting | Phase 1 | 12 | TriArm Therapeutics (Taiwan) LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05703542 | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 24 | Eric Stephen Winer, MDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072494 | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study | recruiting | Phase 1 / Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 144 | Foghorn Therapeutics Inc.INDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07043218 | A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 | 36 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Hangzhou Weben Pharma Co., LtdINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03031249 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | enrolling by invitation | Phase 1 / Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03031262 | Efficacy and Safety of Chidamide in CBF Leukemia | active not recruiting | Phase 1 / Phase 2 | 250 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03512405 | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Oct 14, 2025source: clinicaltrials